Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

IL-15 in the Combination Immunotherapy of Cancer

Frontiers in Immunology(2020)10.3389/fimmu.2020.00868Source: DataRank Database

IL-15 in the Combination Immunotherapy of Cancer is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 4.1. It has been cited 253 times, with 100 citing works in its 1-hop citation network.

N/A

4.1DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access253 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02689453 NCT04150562 NCT03388632 NCT03905135 NCT03759184

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 8.31)OA: goldTopics (32)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 20%Citation Network 80%

Base Score Contribution

0.831

From this paper's citation signal

Citation Network Contribution

3.3

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Cell Research202186 citations33 referencesContributes 0.135
Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
Proceedings of the National Academy of Sciences2022134 citations39 referencesContributes 0.126
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study
Investigative and Clinical Urology202223 citations26 referencesContributes 0.122
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
The Journal of Experimental Medicine202249 citations47 referencesContributes 0.083
Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis
Journal of Cachexia Sarcopenia and Muscle2021133 citations60 referencesContributes 0.082

Authors (4)

Sigrid Dubois ORCID,Miloš D. Miljković ORCID,Kevin C. Conlon ORCID,Thomas A. Waldmann ORCID

Live enrichment

PubMed:32508818 PMC:PMC7248178 OpenAlex:https://openalex.org/W3026299954

FWCI

8.31

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00868/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00868/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fimmu.2020.00868/full

journalhttps://doi.org/10.3389/fimmu.2020.00868

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32508818

Fields of Study

Immune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell Immunology

MeSH Terms

AnimalsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicDrug Therapy, CombinationHumansImmunotherapyNeoplasmsSignal TransductionInterleukin-15Mice

Keywords

MedicineCD8Cytotoxic T cellImmunologyImmunotherapyCD40NivolumabPharmacologyCancer researchInternal medicineImmune systemBiologyIn vitroInterleukin-15Natural killer cellsCd8 T CellsImmunotherapy Of CancerImmunological Checkpoints

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748302.v1figshare

Additional file 1 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748302figshare

Additional file 6 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748317.v1figshare

Additional file 6 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748317figshare

Additional file 7 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748320.v1figshare

Additional file 7 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748320figshare

Additional file 4 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748311.v1figshare

Additional file 5 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748314figshare

Additional file 5 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748314.v1figshare

Additional file 2 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748305figshare

Additional file 4 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748311figshare

Additional file 2 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748305.v1figshare

Additional file 3 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748308.v1figshare

Additional file 3 of Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

10.6084/m9.figshare.26748308figshare